Taurine detected using high-resolution magic angle spinning 1H nuclear magnetic resonance: A potential indicator of early myocardial infarction

Experimental and Therapeutic Medicine

Volumn 5, Issue 3, 2013, Pages 683-688

  Yang, Yunlong ^a,b   Yang, Lin ^c   Zhang, Yue ^a   Gu, Xinghua ^a   Xu, Danling ^a   Fang, Fang ^d   Sun, Aijun ^a   Wang, Keqiang ^a   Yu, Yihua ^d   Zuo, Ji ^b   Ge, Junbo ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^d EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

High performance liquid chromatography; High resolution magic angle spinning; Myocardial infarction; Taurine

Indexed keywords

ALANINE; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; ISOLEUCINE; LACTIC ACID; LEUCINE; PHOSPHORYLCHOLINE; TAURINE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

EID: 84873135380     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.857     Document Type: Article

References (40)

1. Thom T, Haase N, Rosamond W, et al: Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113: e85-e151, 2006.
2. Ilva T, Lassus J, Siirilä-Waris K, et al: Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail10: 772-779, 2008.
3. Bottomley PA and Weiss RG: Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 351: 714-718, 1998.
4. Friess U and Stark M: Cardiac markers: a clear cause for point-of-care testing. Anal Bioanal Chem 393: 1453-1462, 2009.
5. 1H NMR-based metabolomic identification of at-risk areas after myocardial infarction in swine. MAGMA 20: 265-271, 2007.
6. Beer M, Buchner S, Sandstede J, et al: (31)P-MR Spectroscopy for the evaluation of energy metabolism in intact residual myocardium after acute myocardial infarction in humans. MAGMA 13: 70-75, 2001.
7. Cousins JP: Clinical MR spectroscopy: fundamentals, current applications, and future potential. AJR Am J Roentgenol 164: 1337-1347, 1995.
8. Walecki J, Michalak MJ, Michalak E and Pasowicz M: Use of magnetic resonance spectroscopy in cardiology. State of the art. Przegl Lek 59: 601-605, 2002 (In Polish).
9. Horn M: Cardiac magnetic resonance spectroscopy: a window for studying physiology. Methods Mol Med 124: 225-248, 2006.
10. Hudsmith LE and Neubauer S: Magnetic resonance spectroscopy in myocardial disease. JACC Cardiovasc Imaging 2: 87-96, 2009.
11. 31P MRS of heart grafts provides metabolic markers of early dysfunction. Eur J Cardiothorac Surg 28: 576-580, 2005.
12. Beer M, Seyfarth T, Sandstede J, et al: Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40: 1267-1274, 2002.
13. Holloway C, ten Hove M, Clarke K and Neubauer S: MR spectroscopy in heart failure. Front Biosci (Schol Ed) 3: 331-340, 2011.
14. 1H NMR spectroscopic studies on intact rat renal cortex and medulla. Magn Reson Med 41: 1108-1118, 1999.
15. 1H-magnetic resonance spectroscopy in the rat. NMR Biomed 22: 419-425, 2009.
16. 1H NMR spectroscopy. FEBS Lett 553: 73-78, 2003.
17. Griffin JL, Sang E, Evens T, Davies K and Clarke K: Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy. FEBS Lett 530: 109-116, 2002.
18. Jones GL, Sang E, Goddard C, et al: A functional analysis of mouse models of cardiac disease through metabolic profiling. JBiol Chem 280: 7530-7539, 2005.
19. Barba I, de León G, Martin E, et al: Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med 60: 27-32, 2008.
20. Gupta RC, Win T and Bittner S: Taurine analogues; a new class of therapeutics: retrospect and prospects. Curr Med Chem 12: 2021-2039, 2005.
21. Ueno T, Iguro Y, Yotsumoto G, et al: Taurine at early reperfusion significantly reduces myocardial damage and preserves cardiac function in the isolated rat heart. Resuscitation 73: 287-295, 2007.
22. Oriyanhan W, Yamazaki K, Miwa S, Takaba K, Ikeda T and Komeda M: Taurine prevents myocardial ischemia/reperfusion-induced oxidative stress and apoptosis in prolonged hypothermic rat heart preservation. Heart Vessels 20: 278-285, 2005.
23. Hayes KC and Sturman JA: Taurine in metabolism. Annu Rev Nutr 1: 401-425, 1981.
24. Warskulat U, Flögel U, Jacoby C, et al: Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised. FASEB J 18: 577-579, 2004.
25. Heller-Stilb B, van Roeyen C, Rascher K, et al: Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J 16: 231-233, 2002.
26. Liu X, Gu X, Li Z, et al: Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48: 1438-1447, 2006.
27. + exchange. Cardiovasc Res 35: 80-89, 1997.
28. Griffin JL, Mann CJ, Scott J, Shoulders CC and NicholsonJK: Choline containing metabolites during cell transfection: an insight into magnetic resonance spectroscopy detectable changes. FEBS Lett 509: 263-266, 2001.
29. Holmes E, Nicholls AW, Lindon JC, et al: Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem Res Toxicol 13: 471-478, 2000.
30. Lindon JC, Holmes E and Nicholson JK: Pattern recognition methods and applications in biomedical magnetic resonance. Prog Nucl Magn Reson Spectrosc 39: 1-40, 2001.
31. Rowley HL, Martin KF and Marsden CA: Determination of invivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation. JNeurosci Methods 57: 93-99, 1995.
32. Zhu W, Chen J, Cong X, Hu S and Chen X: Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 24: 416-425, 2006.
33. Wang TJ: Significance of circulating troponins in heart failure: if these walls could talk. Circulation 116: 1217-1220, 2007.
34. Collinson PO, Boa FG and Gaze DC: Measurement of cardiac troponins. Ann Clin Biochem 38: 423-449, 2001.
35. Chan CP, Sanderson JE, Glatz JF, Cheng WS, Hempel A and Renneberg R: A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein. Z Kardiol 93: 388-397, 2004.
36. Seino Y, Tomita Y, Takano T and Ohbayashi K; Tokyo Rapid-Test Office Cardiologists (Tokyo-ROC) Study: Office cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ J68: 144-148, 2004.
37. Schaefer S, Schwartz GG, Gober JR, et al: Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia. Phosphorus-31 nuclear magnetic resonance studies of porcine myocardium invivo. J Clin Invest85: 706-713, 1990.
38. Shen W, Asai K, Uechi M, et al: Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation 100: 2113-2118, 1999.
39. Van de Werf F, Bax J, Betriu A, et al: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29: 2909-2945, 2008.
40. Mahrholdt H, Klem I and Sechtem U: Cardiovascular MRI for detection of myocardial viability and ischaemia. Heart 93: 122-129, 2007.